Ifetroban is under clinical development by Cumberland Pharmaceuticals and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Ifetroban’s likelihood of approval (LoA) and phase transition for Hepatorenal Syndrome took place on 15 Sep 2022, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway and decreased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Ifetroban Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Ifetroban overview

Ifetroban (Vasculan, Boxaban, Hepatoren,Portaban) is under development for the treatment of hepatorenal syndrome (HRS), portal hypertension, systemic sclerosis, duchenne muscular dystrophy and aspirin exacerbated respiratory disease (AERD), a respiratory disease involving chronic asthma and nasal polyps. It is also under development for the treatment of  metastatic solid tumors including triple negative breast cancer, pancreatic cancer, lung cancer, esophageal cancers, stomach cancer, progressive fibrosing interstitial lung diseases. The drug candidate is administered through oral route and as infusion through intravenous route. Ifetroban acts by targeting thromboxane A2/prostaglandin H2 receptor.

It was under development for the treatment of pacing-induced ischemia, squamous cell carcinoma (SCCA).

Cumberland Pharmaceuticals overview

Cumberland Pharmaceuticals (Cumberland), is a specialty pharmaceutical company that acquires, develops, and commercializes branded prescription products. Its primary target markets are hospital acute care, gastroenterology, and cancer supportive care. The company offers branded prescription products under Acetadote, Caldolor, Kristalose, Omeclamox, Vaprisol, Ethyol, Totect, Hepatoren, Boxaban, Vasculan, Portaban, and RediTrex brand names. Cumberland Pharma promotes approved products through its hospital and gastroenterology sales forces in the US. The company is also establishing a network of international partners to commercialize its products in their countries. Cumberland Pharma is headquartered in Nashville, Tennessee, the US.

Quick View Ifetroban LOA Data

Report Segments
  • Innovator
Drug Name
  • Ifetroban
Administration Pathway
  • Intravenous
  • Oral
  • Parenteral
Therapeutic Areas
  • Cardiovascular
  • Gastrointestinal
  • Genetic Disorders
  • Immunology
  • Oncology
  • Respiratory
Key Developers
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.